MannKind Corporation is a biopharmaceutical company with a primary focus on developing and commercializing inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company's flagship product is Afrezza, an inhaled insulin designed to enhance glycemic control in adults with diabetes. Additionally, MannKind offers the innovative V-Go wearable insulin delivery device that provides continuous subcutaneous infusion of insulin for adults. MannKind's product pipeline includes Tyvaso DP Treprostinil, an inhalation powder designed to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company is also developing MNKD-101, a nebulized formulation of clofazimine, aimed at treating severe chronic and recurrent pulmonary infections such as nontuberculous mycobacterial lung disease, idiopathic pulmonary, and cystic fibrosis. In partnership with United Therapeutics Corporation, MannKind has a collaboration and license agreement for development, regulatory, and commercial activities of Tyvaso DPI. Furthermore, MannKind has a co-promotion agreement with Vertice Pharma to promote Thyquidity and a collaboration agreement with Thirona to assess a therapeutic for treating pulmonary fibrosis. MannKind's reach extends globally with their supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil and their license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. Established in 1991, MannKind Corporation is headquartered in Danbury, Connecticut.
MannKind's ticker is MNKD
The company's shares trade on the NASDAQ stock exchange
They are based in Westlake Village, California
There are 201-500 employees working at MannKind
It is mannkindcorp.com
MannKind is in the Healthcare sector
MannKind is in the Biotechnology industry
The following five companies are MannKind's industry peers: